BACKGROUND: The aim of the study was to determine whether CHADS(2) score is predictive of left atrial appendage thrombus (LAAT) in nonvalvular atrial fibrillation (AF). Strategies for effective stroke prevention in AF require tools capable of identifying those patients at greatest risk for embolization of LAAT and most likely to benefit from warfarin. Nearly half of strokes in AF are due to noncardioembolic mechanisms for which antiplatelet therapy would be more appropriate. Previous attempts to develop such tools have been limited by including patients without proven cardioembolism. METHODS: Nonanticoagulated, nonvalvular AF patients with (cases) or without (controls) LAAT by transesophageal echocardiography were identified using Mayo Clinic Echocardiography and Cardioversion Unit Databases (Rochester, MN). Type and duration of AF, CHADS(2) score, and echocardiography measures were compared to determine variables predictive of LAAT. RESULTS: The CHADS(2) score was significantly higher for cases (n = 110, mean +/- SD 2.8 +/- 1.6) compared to controls (n = 387, 1.6 +/- 1.3). By multivariate analysis, independent predictors of LAAT included heart failure (HR 5.78, P < 0001), prior stroke/transient ischemic attack (HR 3.94, P < .0001), diabetes mellitus (HR 1.98, P = .015), permanent AF (HR 3.02, P < .05), AF duration (HR 2.24, P < .05), and spontaneous echocardiographic contrast (HR 4.35, P = .005). Using these elements, a new scoring system provided cleaner case-control separation (C-index 0.90) and higher predictive power compared to CHADS(2) (C-index 0.71). CONCLUSIONS: The CHADS(2) score predicts the presence of LAAT in AF patients. Some, but not all, variables within this score are predictive of LAAT. By including only echo and clinical variables predictive of LAAT, our novel scoring system better identified those AF patients at greatest cardioembolic risk. Copyright 2010 Mosby, Inc. All rights reserved.
BACKGROUND: The aim of the study was to determine whether CHADS(2) score is predictive of left atrial appendage thrombus (LAAT) in nonvalvular atrial fibrillation (AF). Strategies for effective stroke prevention in AF require tools capable of identifying those patients at greatest risk for embolization of LAAT and most likely to benefit from warfarin. Nearly half of strokes in AF are due to noncardioembolic mechanisms for which antiplatelet therapy would be more appropriate. Previous attempts to develop such tools have been limited by including patients without proven cardioembolism. METHODS: Nonanticoagulated, nonvalvular AFpatients with (cases) or without (controls) LAAT by transesophageal echocardiography were identified using Mayo Clinic Echocardiography and Cardioversion Unit Databases (Rochester, MN). Type and duration of AF, CHADS(2) score, and echocardiography measures were compared to determine variables predictive of LAAT. RESULTS: The CHADS(2) score was significantly higher for cases (n = 110, mean +/- SD 2.8 +/- 1.6) compared to controls (n = 387, 1.6 +/- 1.3). By multivariate analysis, independent predictors of LAAT included heart failure (HR 5.78, P < 0001), prior stroke/transient ischemic attack (HR 3.94, P < .0001), diabetes mellitus (HR 1.98, P = .015), permanent AF (HR 3.02, P < .05), AF duration (HR 2.24, P < .05), and spontaneous echocardiographic contrast (HR 4.35, P = .005). Using these elements, a new scoring system provided cleaner case-control separation (C-index 0.90) and higher predictive power compared to CHADS(2) (C-index 0.71). CONCLUSIONS: The CHADS(2) score predicts the presence of LAAT in AFpatients. Some, but not all, variables within this score are predictive of LAAT. By including only echo and clinical variables predictive of LAAT, our novel scoring system better identified those AFpatients at greatest cardioembolic risk. Copyright 2010 Mosby, Inc. All rights reserved.
Authors: Sakima A Smith; Philip F Binkley; Randi E Foraker; Haikady N Nagaraja; David A Orsinelli Journal: J Am Soc Echocardiogr Date: 2012-06-29 Impact factor: 5.251
Authors: Kevin P Cohoon; Matylda Mazur; Robert D McBane; Siva Ketha; Naser Ammash; Waldemar E Wysokinski Journal: Int J Cardiol Date: 2014-12-03 Impact factor: 4.164
Authors: Kevin P Cohoon; Robert D McBane; Naser Ammash; Joshua P Slusser; Diane E Grill; Waldemar E Wysokinski Journal: J Thromb Thrombolysis Date: 2016-05 Impact factor: 2.300
Authors: F Zoppo; G Brandolino; A Berton; N Frigato; M Michieletto; A Zanocco; F Zerbo; E Bacchiega; A Lupo; E Bertaglia Journal: J Interv Card Electrophysiol Date: 2012-08-07 Impact factor: 1.900
Authors: W E Wysokinski; K P Cohoon; R M Melduni; M Mazur; N Ammash; T Munger; E Konik; T McLeod; Izabeal Gosk-Bierska; R D McBane Journal: Thromb Res Date: 2018-10-10 Impact factor: 3.944
Authors: Rami Doukky; Enrique Garcia-Sayan; Heather Gage; Vijaiganesh Nagarajan; Anna Demopoulos; Marek Cena; Noreen T Nazir; George J Karam; Richard G Trohman; Rasa Kazlauskaite Journal: Cardiovasc Ultrasound Date: 2014-02-25 Impact factor: 2.062